Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRiSM: PrP-siRNA in Symptomatic and Pre-symptomatic Prion Disease
NCT07444580Phase 1Recruiting
- Sponsor
- Broad Institute
- Start
- May 2026
- Primary completion
- Aug 2029
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, open-label trial of PrP-siRNA in Prion Disease (PD) (3 arms), sponsored by Broad Institute. Primary endpoint: Frequency of adverse events at 24 weeks. Started May 2026; status: recruiting.
02
Drugs
PrP-siRNA
03
Conditions
Prion Disease (PD)
Beyond the preview
Go deeper on NCT07444580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07444580.